hit counter
Agios Pharmaceuticals, Inc. (AGIO) Stock News Sentiment & Price - Sentifly
AGIO - Sentifly



Your watchlist is empty. Go add some tickers to it!

Agios Pharmaceuticals, Inc. (AGIO)

AGIO Price and Sentiment
Positive, Negative
Loading chart...
AGIO Latest news
Zacks Investment Research
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
12 minutes ago

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
2021-10-21 16:01

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights.

Seeking Alpha
Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced
2021-09-07 09:36

Comparisons with AGIO are from hundreds of biotech product developers viewed continually by institutional investors as capital gain sources. Values are based on how market professionals protect their own capital, put at risk in order to fill multi-million-$ trade orders placed by institutions managing multi-Billion-$ portfolios.

Agios To Present at September Investor Conferences
2021-08-30 07:00

CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:

7 Best Biotech Stocks to Buy in 2021 with Huge Upside
2021-08-25 12:08

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

Zacks Investment Research
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
2021-08-18 11:29

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

Agios' Rare Anemia Drug Application Under FDA Priority Review
2021-08-18 07:03

The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agency's action date is assigned as of February 17, 2022.

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
2021-08-17 16:01

-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --

Zacks Investment Research
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
2021-07-30 13:41

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

24/7 Wall Street
Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades
2021-07-30 11:48

With the trading day nearly halfway over, the broad markets were pulling back into the weekend.

Loading more news...